Castle Biosciences to Host Investor Day on Sept. 20, 2022
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) will host an Investor Day on Sept. 20, 2022, from 4:00 p.m. to 6:30 p.m. EDT, featuring insights on corporate strategy, growth plans, and financial outlook. Key executives, including Derek Maetzold and Frank Stokes, will lead the discussions. Attendees can register for the virtual event via the company's investor relations page. Castle focuses on innovative diagnostic tests for various health conditions, aiming to enhance patient care.
Positive
None.
Negative
None.
Insights
Analyzing...
FRIENDSWOOD, Texas--(BUSINESS WIRE)--
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will host an Investor Day on Sept. 20, 2022.
Derek Maetzold, president and chief executive officer, Frank Stokes, chief financial officer, and other members of Castle’s executive leadership team will provide an overview of the Company’s long-term corporate strategy, growth plans, research and development initiatives and financial outlook.
Castle’s Investor Day event is scheduled to begin at 4:00 p.m. EDT and conclude at 6:30 p.m. EDT, followed by a Question & Answer session.
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, Twitter and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, myPath Melanoma, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.